阿卡波糖联合艾塞那肽治疗2型糖尿病的临床效果

Clinical Effect of Acarbose Combined with Exenatide in the Treatment of Type 2 Diabetes

目的探讨阿卡波糖联合艾塞那肽治疗2型糖尿病(T2DM)的临床效果。方法选择2020年2月至2021年2月在夏邑县人民医院接受治疗的80例T2DM患者作为研究对象,根据随机数表法分为两组,各40例。两组患者均接受常规运动及饮食干预,在此基础上,对照组口服阿卡波糖治疗,观察组接受阿卡波糖联合艾塞那肽治疗,共治疗3个月。比较两组血糖指标、胰岛功能、炎症水平及治疗期间不良反应发生情况。结果治疗3个月,观察组空腹血糖(FBG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)水平低于对照组(P<0.05),空腹胰岛素(INS)、餐后2 h胰岛素(2 h INS)、稳态模型胰岛β细胞功能指数(HOMA-β)高于对照组,稳态模型胰岛素抵抗指数(HOMA-IR)低于对照组(P<0.05)。治疗3个月,观察组血清肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)水平低于对照组(P<0.05)。两组间不良反应发生率相比,差异无统计学意义(P>0.05)。结论阿卡波糖联合艾塞那肽可有效降低T2DM患者血糖水平,减轻炎症反应,改善胰岛功能。

Objective To investigate the clinical effect of acarbose combined with exenatide in the treatment of type 2 diabetes(T2DM).Methods Eighty patients with T2DM who were treated at Xiayi County People’s Hospital from February 2020 to February 2021 were selected as the research objects,and were divided into two groups according to the random number table method,with forty cases in each group.Both groups of patients received routine exercise and diet intervention.On this basis,control group received acarbose orally,and observation group received acarbose combined with exenatide for a total of 3 months.The two groups of blood glucose indicators,islet function,inflammation level and the occurrence of adverse reactions during treatment were compared.Results After 3 months of treatment,the fasting blood glucose(FBG),2 h postprandial blood glucose(2 h PG),and glycosylated hemoglobin(HbA1c)levels of the observation group were lower than those of the control group(P<0.05).In observation group,fasting insulin(INS),2 h postprandial insulin(2 h INS),homeostasis model assessment of β cell function(HOMA-β)were higher than those in control group,and homeostasis model assessment-insulin resistance index(HOMA-IR)was lower than that in control group(P<0.05).After 3 months of treatment,the serum tumor necrosis factor-α(TNF-α)and interleukin-6(IL-6)levels in observation group were lower than those in control group(P<0.05).There was no statistical difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Acarbose combined with exenatide could effectively reduce blood glucose levels in patients with T2DM,reduce inflammation,and improve islet function.